New Alzheimer’s drug aducanumab is dividing doctors and patients, as the TGA weighs up its risk-benefit profile – ABC News

After a decades-long career as a biology teacher, John Rodgers applies the strict logic of a scientist to answer tough questions.
So, when it comes to his mortality, he is equally rational.
“I either want it to end quickly or get better,” he said.
Key points:
…

Click here to view the original article.